Edwards Lifesciences Corp. hopes to build on the success of its Sapien transcatheter aortic valve replacement system by developing transcatheter mitral valve replacement technology. And other companies are at a close pace in pursuing what could me a massive market with significant clinical need.
Mitral valve disease is the most common type of heart valve condition in the U.S., and about 8 to 12 percent of the population will eventually develop significant mitral regurgitation,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?